Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

Biotech has aligned its internal focus on CAR NKs, but may partner elsewhere

January 6, 2021 11:14 PM UTC
Updated on Jan 12, 2021 at 5:30 PM UTC

The latest signal of Bayer’s growing interest in gene and cell therapies is its investment in synthetic biology company Senti, whose gene circuit technology gives the biotech both an internal pipeline and a partnering opportunity.

The pharma’s Leaps by Bayer venture arm led a $105 million series B round Wednesday for Senti, which was co-founded by CEO Tim Lu...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Bayer AG

Senti Biosciences Inc.